804 related articles for article (PubMed ID: 33971168)
1. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
McDowell PJ; Diver S; Yang F; Borg C; Busby J; Brown V; Shrimanker R; Cox C; Brightling CE; Chaudhuri R; Pavord ID; Heaney LG;
Lancet Respir Med; 2021 Oct; 9(10):1174-1184. PubMed ID: 33971168
[TBL] [Abstract][Full Text] [Related]
2. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
3. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
[TBL] [Abstract][Full Text] [Related]
4. Anti-IL5 therapies for asthma.
Farne HA; Wilson A; Powell C; Bax L; Milan SJ
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516
[TBL] [Abstract][Full Text] [Related]
5. Anti-IL-5 therapies for asthma.
Farne HA; Wilson A; Milan S; Banchoff E; Yang F; Powell CV
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD010834. PubMed ID: 35838542
[TBL] [Abstract][Full Text] [Related]
6. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.
Busse WW; Wenzel SE; Casale TB; FitzGerald JM; Rice MS; Daizadeh N; Deniz Y; Patel N; Harel S; Rowe PJ; Graham NMH; O'Riordan T; Pavord ID
Lancet Respir Med; 2021 Oct; 9(10):1165-1173. PubMed ID: 34181876
[TBL] [Abstract][Full Text] [Related]
7. Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial.
Jackson DJ; Bacharier LB; Gergen PJ; Gagalis L; Calatroni A; Wellford S; Gill MA; Stokes J; Liu AH; Gruchalla RS; Cohen RT; Makhija M; Khurana Hershey GK; O'Connor GT; Pongracic JA; Sherenian MG; Rivera-Spoljaric K; Zoratti EM; Teach SJ; Kattan M; Dutmer CM; Kim H; Lamm C; Sheehan WJ; Segnitz RM; Dill-McFarland KA; Visness CM; Becker PM; Gern JE; Sorkness CA; Busse WW; Altman MC;
Lancet; 2022 Aug; 400(10351):502-511. PubMed ID: 35964610
[TBL] [Abstract][Full Text] [Related]
8. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.
Khurana S; Brusselle GG; Bel EH; FitzGerald JM; Masoli M; Korn S; Kato M; Albers FC; Bradford ES; Gilson MJ; Price RG; Humbert M
Clin Ther; 2019 Oct; 41(10):2041-2056.e5. PubMed ID: 31447130
[TBL] [Abstract][Full Text] [Related]
9. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
Pavord ID; Korn S; Howarth P; Bleecker ER; Buhl R; Keene ON; Ortega H; Chanez P
Lancet; 2012 Aug; 380(9842):651-9. PubMed ID: 22901886
[TBL] [Abstract][Full Text] [Related]
10. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
Brightling CE; Bleecker ER; Panettieri RA; Bafadhel M; She D; Ward CK; Xu X; Birrell C; van der Merwe R
Lancet Respir Med; 2014 Nov; 2(11):891-901. PubMed ID: 25208464
[TBL] [Abstract][Full Text] [Related]
11. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
Bernstein JA; Virchow JC; Murphy K; Maspero JF; Jacobs J; Adir Y; Humbert M; Castro M; Marsteller DA; McElhattan J; Hickey L; Garin M; Vanlandingham R; Brusselle G
Lancet Respir Med; 2020 May; 8(5):461-474. PubMed ID: 32066536
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
[TBL] [Abstract][Full Text] [Related]
13. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison TW; Chanez P; Menzella F; Canonica GW; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; McDermott L; Garcia Gil E; Zangrilli JG;
Lancet Respir Med; 2021 Mar; 9(3):260-274. PubMed ID: 33357499
[TBL] [Abstract][Full Text] [Related]
14. Mepolizumab and exacerbations of refractory eosinophilic asthma.
Haldar P; Brightling CE; Hargadon B; Gupta S; Monteiro W; Sousa A; Marshall RP; Bradding P; Green RH; Wardlaw AJ; Pavord ID
N Engl J Med; 2009 Mar; 360(10):973-84. PubMed ID: 19264686
[TBL] [Abstract][Full Text] [Related]
15. Exhaled nitric oxide levels to guide treatment for children with asthma.
Petsky HL; Kew KM; Chang AB
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD011439. PubMed ID: 27825189
[TBL] [Abstract][Full Text] [Related]
16. Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response.
Caminati M; Cegolon L; Vianello A; Chieco Bianchi F; Festi G; Marchi MR; Micheletto C; Mazza F; Tognella S; Senna G
Expert Rev Respir Med; 2019 Dec; 13(12):1205-1212. PubMed ID: 31592700
[No Abstract] [Full Text] [Related]
17. Small airway dysfunction as predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: a longitudinal observational study.
Abdo M; Watz H; Veith V; Kirsten AM; Biller H; Pedersen F; von Mutius E; Kopp MV; Hansen G; Waschki B; Rabe KF; Trinkmann F; Bahmer T
Respir Res; 2020 Oct; 21(1):278. PubMed ID: 33087134
[TBL] [Abstract][Full Text] [Related]
18. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils).
Petsky HL; Cates CJ; Lasserson TJ; Li AM; Turner C; Kynaston JA; Chang AB
Thorax; 2012 Mar; 67(3):199-208. PubMed ID: 20937641
[TBL] [Abstract][Full Text] [Related]
19. Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma.
Albers FC; Licskai C; Chanez P; Bratton DJ; Bradford ES; Yancey SW; Kwon N; Quirce S
Respir Med; 2019 Nov; 159():105806. PubMed ID: 31751853
[TBL] [Abstract][Full Text] [Related]
20. Exhaled nitric oxide levels to guide treatment for adults with asthma.
Petsky HL; Kew KM; Turner C; Chang AB
Cochrane Database Syst Rev; 2016 Sep; 9(9):CD011440. PubMed ID: 27580628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
